Rapcabtagene autoleucel
- Generic Name
- Rapcabtagene autoleucel
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Phase 2
Recruiting
- Conditions
- ANCA Associated Vasculitis (AAV)
- Interventions
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 126
- Registration Number
- NCT06868290
- Locations
- ๐บ๐ธ
Oregon Health Sciences University, Portland, Oregon, United States
๐ธ๐ฌNovartis Investigative Site, Singapore, Singapore
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Phase 2
Recruiting
- Conditions
- Idiopathic Inflammatory Myopathies
- Interventions
- Other: Active Comparator Option
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 123
- Registration Number
- NCT06665256
- Locations
- ๐บ๐ธ
Northwestern University, Chicago, Illinois, United States
๐บ๐ธUniversity Of Iowa, Iowa City, Iowa, United States
๐จ๐ณNovartis Investigative Site, Taichung, Taiwan
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Phase 2
Recruiting
- Conditions
- Scleroderma, Diffuse
- Interventions
- First Posted Date
- 2024-10-24
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 86
- Registration Number
- NCT06655896
- Locations
- ๐บ๐ธ
UCSF, San Francisco, California, United States
๐บ๐ธUniversity Of Iowa, Iowa City, Iowa, United States
๐บ๐ธMichigan Med University of Michigan, Ann Arbor, Michigan, United States
An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus
Phase 1
Active, not recruiting
- Conditions
- Lupus NephritisSystemic Lupus Erythematosus
- Interventions
- First Posted Date
- 2023-04-04
- Last Posted Date
- 2025-04-22
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT05798117
- Locations
- ๐บ๐ธ
Division of Rheumatology Immunology, Birmingham, Alabama, United States
๐จ๐ญNovartis Investigative Site, Lausanne, Switzerland
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath